By Daniella Parra
Swiss life sciences company Lunaphore presented data on the capabilities of its COMET platform in the study of the immune status of the tumor microenvironment, the company said in a statement.
The research focused on immune checkpoint biomarkers and the immune contexture of Hepatoblastoma (HB), a pediatric liver cancer, Lunaphore said.
“We want to develop a signature that could easily triage those two types of HB and understand why HB patients respond to chemotherapies,” said Dr. Aurore Pire, Pediatric Surgeon and Ph.D. student at CRC. “If some patients could benefit from these markers of response to anti-PD-(L)1 immunotherapies, that could be a major win for them.”